Breaking: Pfizer settles Vyndamax (tafamidis) suit
It has been confirmed today that Pfizer settled with the final defendant, Hikma Pharmaceuticals.
It has been confirmed today that Pfizer settled with the final defendant, Hikma Pharmaceuticals.
Update from the Vyndamax (tafamidis) trial: Hikma Pharmaceuticals, the holdout defendant, no longer appears to be challenging the validity of Pfizer’s patent.
BREAKING - Pfizer (PFE) SETTLES Tafamidis suit with two of three defendants. Key question for analysts - how long will Pfizer’s patent protection last under the settlement? Based on available research, generics could be out of the market…
Analysts are looking ahead to the tafamidis patent trial involving Pfizer (NYSE: PFE), as recent court developments begin to shape investor expectations ahead of the proceedings next week.
A court case between Pfizer (PFE) and generic drug manufacturers, which will determine control of the $16.5 billion-plus Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market, is less than two weeks away.